HDAC 抑制剂终于问世：CTCL 的染色质可及性特征。
HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
出版信息
Cancer Cell. 2017 Jul 10;32(1):1-3. doi: 10.1016/j.ccell.2017.06.008.
In this issue of Cancer Cell, Qu et al. describe the chromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of response and resistance to histone deacetylase inhibitor therapy. Their "personal regulome" analysis framework reveals chromatin features that may be predictive of clinical response to epigenetic therapy.
在本期《癌细胞》中，瞿等描述了皮肤 T 细胞淋巴瘤的染色质可及性图谱，并对组蛋白去乙酰化酶抑制剂治疗的反应和耐药进行了动态评估。他们的“个人调控组”分析框架揭示了可能预测表观遗传治疗临床反应的染色质特征。
Zotero 插件